Granulox is a new medical device for the care of chronic wounds. It is sold by SastoMed GmbH and Diapharm is assuming the legal role of manufacturer.
Looking forward, Diapharm will also be performing the legal role of manufacturer of the wound spray through its ISO 13485 certified subsidiary HÄLSA Pharma GmbH. Manufacturing and batch release of the medical device will take place under the HÄLSA quality management system. Granulox is on sale now.
Granulox wound spray new on the market
“This wound spray makes it possible to apply a known principle in an uncomplicated manner for the first time – both in hospitals and in an outpatient setting,” explains Michael Sander, Director of SastoMed GmbH. As a result of easier diffusion, the haemoglobin in the product transports oxygen from the air to the wound bed and improves oxygen supply. Certification as a Class III medical device has been particularly ambitious, emphasises Sander, whose company has obtained the world-wide patent rights and rights of sale for the technology: “We are grateful to Diapharm that market release in Europe has now come about so quickly.” The technology behind Granulox comes from Sangui Bio Tech. The efficacy of the physical process has been proven in clinical trials.
(approx. 1,620 characters)